Clinical trial
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT02713386 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Lead sponsor
- NRG Oncology
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 14, 2016
- Completion date
- May 22, 2024
- Enrollment
- 147 (actual)
- Sites
- 110
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube high grade serous adenocarcinoma, figo stage iii ovarian cancer 2014, figo stage iiia ovarian cancer 2014, figo stage iiia1 ovarian cancer, figo stage iiia2 ovarian cancer, figo stage iiib ovarian cancer 2014, figo stage iiic ovarian cancer 2014, figo stage iva ovarian cancer 2014, figo stage ivb ovarian cancer 2014, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, primary peritoneal endometrioid adenocarcinoma, primary peritoneal high grade serous adenocarcinoma, stage iii fallopian tube cancer ajcc v7, stage iii primary peritoneal cancer ajcc v7, stage iiia fallopian tube cancer ajcc v7, stage iiia primary peritoneal cancer ajcc v7, stage iiib fallopian tube cancer ajcc v7, stage iiib primary peritoneal cancer ajcc v7, stage iiic fallopian tube cancer ajcc v7, stage iiic primary peritoneal cancer ajcc v7, stage iv fallopian tube cancer ajcc v6 and v7, stage iv primary peritoneal cancer ajcc v7